The clinical trial, involving 40 patients at the Singapore General Hospital (SGH) and the National Cancer Centre Singapore ...

In today’s health headlines, a physician-scientist tells us about liver cancer care here in New Haven, what your life may look like after certain liver cancer ...

Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic ...

A novel molecular imaging agent targeting glypican-3 (GPC3) has demonstrated high sensitivity and specificity in detecting ...

Massey Comprehensive Cancer Center have discovered a new genetic target that could possibly shape the future of treatment for liver ...

A novel molecular imaging agent targeting glypican-3 (GPC3) has demonstrated high sensitivity and specificity in detecting ...

Hepatocellular carcinoma (HCC), the most common type of liver cancer and the third-leading cause of cancer-related deaths ...

Prior authorization varies by plan but often requires patients or their providers to get permission (also called ...

At Miami-Dade’s public hospital system Jackson Health, new advancements in genetic research recently helped doctors modify a ...

Affiliates: Chan Zuckerberg Biohub New York, Vagelos Institute for Biomedical Research, Irving Institute for Clinical and Translational Research, Vagelos College of Physicians and Surgeons Departments ...

A RECENT international Phase 3 clinical trial has demonstrated that a combination of toripalimab and bevacizumab significantly improves survival outcomes in patients with previously untreated advanced ...

Millions of prior authorization denials are made annually, leaving many patients stuck in a convoluted appeals process. For doctors, these decisions are frustrating. For patients, they can be ...